November 28, 2023 AlzeCure presents at DNB Nordic-American Healthcare Conference in New York December 6-7
October 25, 2023 AlzeCure presents disease-modifying data with NeuroRestore ACD856 at Alzheimer’s conference CTAD
October 17, 2023 AlzeCure publishes new article on the GSM mechanism behind Alzstatin against Alzheimer’s disease
October 12, 2023 AlzeCure presents clinical phase II-data with ACD440 for neuropathic pain at pain conference
September 26, 2023 AlzeCure gets presentation accepted on disease-modifying effects of ACD856 at Alzheimer’s conference
September 20, 2023 AlzeCure presents positive phase II clinical data with ACD440 against neuropathic pain at EFIC 2023 Conference
September 18, 2023 AlzeCure gets an abstract on phase II clinical data with ACD440 for neuropathic pain accepted at pain conference
August 9, 2023 AlzeCure publishes the positive clinical results from the phase I trial of NeuroRestore ACD856 against Alzheimer’s
July 11, 2023 AlzeCure publishes new disease modifying data with NeuroRestore ACD856 against Alzheimer’s and cognitive disorders
June 13, 2023 New article on disease modifying data with NeuroRestore ACD856 against Alzheimer’s now available online
May 24, 2023 AlzeCure announces positive Phase IIa clinical study data in neuropathic pain with the non-opioid ACD440
April 19, 2023 AlzeCure gets an abstract on non-opioid ACD440 for neuropathic pain accepted at the EFIC 2023 Conference
March 30, 2023 AlzeCure presents new data at Alzheimer’s conference AD/PD on the potential disease-modifying effect of NeuroRestore ACD856
March 28, 2023 AlzeCure presents new data on its preventive treatment Alzstatin at the Alzheimer’s conference AD/PD 2023
March 13, 2023 AlzeCure achieves Last Patient Last Visit (LPLV) in its phase II clinical trial of the non-opioid ACD440 in neuropathic pain
January 31, 2023 Last patient included in AlzeCure’s Phase II clinical trial in peripheral neuropathic pain with the non-opioid ACD440
January 11, 2023 AlzeCure selects CD and enters next development phase with Alzstatin ACD680 against Alzheimer’s
